A significant development in the private equity space has captured the attention of analysts and investors alike. New Mountain Capital has successfully raised approximately $3 billion in funds to support the further development of Real Chemistry. This deal ranks among the largest in the history of single-asset acquisitions, highlighting the growing interest in the biopharmaceutical sector.